Contact
searchSearch
HMP Global

Nasal Polyps Topic Center

Featured Article

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
Headshot of Peter Lio, MD, FAAD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Addressing Unmet Needs in Patients With Type 2 Inflammatory Conditions
09/28/2021
Edan Stanley
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical...
09/28/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
First Treatment Approved for Chronic Rhinosinusitis With Nasal Polyps
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Challenge of Long-term Control

Newsfeed

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
First Treatment Approved for Chronic Rhinosinusitis With Nasal Polyps
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care
Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
News
Differences in OUD Treatment Coverage Across Medicaid Managed Care Plans From 2015 to 2019
05/26/2026
Rebecca Amrick
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Comorbidities Increase Clinical and Economic Burden for Patients With Chronic Kidney Disease
05/22/2026
Rebecca Amrick
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden...
05/22/2026
First Report Managed Care
News
Pembrolizumab Plus Chemotherapy Improves Survival in mNSCLC at Higher Cost
05/22/2026
Rebecca Amrick
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy...
05/22/2026
First Report Managed Care
Behind the Bill
Congress Targets Enforcement Gaps in the No Surprises Act
05/22/2026
Hannah Musick
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to...
05/22/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care
News
The Effect of Nephologist Affiliation on PD Utilization for Patients With ESKD
05/20/2026
Rebecca Amrick
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that...
05/20/2026
First Report Managed Care
News
Ponatinib Demonstrates Greater Clinical Benefit Than Imatinib but With Significantly Higher Care Costs
05/20/2026
Rebecca Amrick
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor...
05/20/2026
First Report Managed Care
News
Severe Alcohol-Associated Hepatitis Raises Health Care Costs Across Multiple Care Settings
05/18/2026
Rebecca Amrick
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for...
05/18/2026
First Report Managed Care

Recent Articles

News
Eosinophilic Esophagitis Symptoms Improved by Monoclonal Antibody Therapy
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
Dupilumab Improves Symptoms in Patients With Severe CRSwNP and Comorbid Asthma
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
Headshot of Peter Lio, MD, FAAD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Addressing Unmet Needs in Patients With Type 2 Inflammatory Conditions
09/28/2021
Edan Stanley
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical assistant professor of dermatology & pediatrics, Northwestern University Feinberg School of Medicine, and founding director, Chicago Integrative Eczema Center, discusses the common challenges associated with...
Peter Lio, MD, FAAD, clinical...
09/28/2021
First Report Managed Care
News
Dupilumab offers relief for severe chronic rhinosinusitis with nasal polyps
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
Lower QoL Among Patients With Chronic Rhinosinusitis With Nasal Polyps
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use